Leadership Team

Lisa Earnhardt

President and Chief Executive Officer


Lisa joined Intersect ENT in 2008 as President and Chief Executive Officer and has led the company from early clinical stage. Previously, Lisa was President of Boston Scientific’s Cardiac Surgery division. Lisa has over two decades of experience in healthcare, primarily in leading global product launches and driving adoption of new medical technologies at both Boston Scientific and Guidant in a variety of sales and marketing leadership roles. Lisa began her career at APM/CSC Healthcare where she provided management consulting services to healthcare provider organizations. She serves on the boards of Intersect ENT and Nevro Corporation (NYSE: NVRO). Lisa is a member of the board of directors of Advanced Medical Technology Association (AdvaMed), the Kellogg Global Advisory board, and Young Presidents’ Organization. Lisa holds a B.S. in Industrial Engineering from Stanford University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.

Jeryl (Jeri) Hilleman

Chief Financial Officer


Jeri has served as our Chief Financial Officer since 2014, just prior to our IPO. She brings over 20 years of experience as a CFO, including taking 5 companies public.  Previously, she served as CFO of public companies including Amyris (NASDAQ: AMRS), a renewable products company, Symyx Technologies (acquired), a materials science research, instrumentation and software company, Ocera (acquired), a biopharma company, and Cytel (acquired), an immunotherapy company. Ms. Hilleman is a member of the Board of Directors and Audit Committees of NovoCure (NASDAQ: NVCR), a commercial global oncology company, and Minerva Neurosciences (NASDAQ: NERV), a biopharma company focused on central nervous system disorders, and she served previously as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (acquired), a commercial biopharma company. Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

David Lehman

General Counsel


David serves as in-house general counsel. He was previously with Thoratec, a global leader in medical technology to address advanced stage heart failure, as Vice President, General Counsel and Secretary (since May 2003) and Senior Vice President (since 2007) prior to Thoratec’s sale to St. Jude Medical in 2015. Prior to that, he was Vice President and General Counsel at Brigade Corporation, a business process outsourcing company, and previously held positions in the legal departments of Bio-Rad Laboratories, Inc., a life science research and clinical diagnostics company, and Mitsubishi International Corporation, a Japanese trading company, in their New York and Tokyo offices. He began his career as an associate attorney at the law firm of Hall, Dickler, Kent, Friedman & Wood in New York. David holds a B.A. in political science from The University of California, San Diego and a J.D. from Cornell University Law School.

Robert Binney

Chief Commercial Officer


Rob has extensive sales leadership, sales training and sales execution experience in the medical device and pharmaceutical industries. Prior to joining Intersect ENT, Rob was Director of Sales for AccessClosure, Inc., a privately-held medical device company where Rob successfully built and led a team of 60 sales professionals, playing a significant role in the organization’s growth from no sales in June 2007 to over $70 million in 2010. Previously, Rob was a top performing sales professional and trainer at Boston Scientific in the peripheral and vascular surgery markets. He began his medical sales career with Aventis Pharmaceuticals and holds a B.A. in Communications from the University of North Carolina at Chapel Hill.

Gwen Carscadden

Chief People Officer


Gwen joined the team in June of 2016, and serves as Intersect ENT’s Chief People Officer. She has over 25 years of experience in Human Resources in both high technology and life sciences sectors. Prior to joining Intersect ENT, Gwen served as Senior Vice President of Human Resources at CardioDx, Inc. a privately held Medical Diagnostics company. Before that, Gwen was Vice President of Human Resources for Facet Biotech, which was acquired by Abbott Laboratories. She served as an Executive Director of Human Resources for PDL Biopharma, and she began her career in the technology sector, working for Amdahl Corporation and Fujitsu Computer Systems. Gwen holds an M.A. in Organizational Communication from San Jose State University and a B.A. in Behavioral Sciences also from San Jose State.

Virginia Giddings

Vice President of Research & Development


Virginia joined Intersect ENT in 2019 and serves as Vice President of Research & Development, driving the transformation and expansion of the company’s product portfolio. Virginia has extensive experience in healthcare leadership, with roles in medical device, pharmaceutical and nutrition businesses. She was previously with Stryker Neurovascular, where she led Advanced Technologies and Innovation, driving cultural change and new approaches to disruptive innovation for the treatment of stroke. In addition, she led the Program Management Office, where she was responsible for delivering the complete product development portfolio, as well as key business initiatives and commercial launch management. Prior to Stryker, she ran Strategic R&D for the Nutrition division at Abbott, with global responsibility for early-stage research and science partnerships. Virginia also played a key role in the FDA approval of Abbott’s drug eluting coronary stent and led the technical strategy for Abbott’s novel bioabsorbable stent, resulting in a first-of-its-kind CE Mark approval. She was responsible for developing IP strategy for drug-device combination products while with ALZA, a Johnson & Johnson Pharmaceutical company. She serves on the Cornell Engineering Council, President’s Council of Cornell Women and Georgia Tech-Emory Bioengineering Board. In addition, she is a Fellow of the American Institute of Medical and Biological Engineering and a co-founder of MedtechWomen, an organization dedicated to highlighting and connecting women leaders in healthcare. Virginia holds both B.S. and M.Eng. degrees in Mechanical Engineering from Cornell University, and a Ph.D. in Mechanical Engineering from Stanford University.

Christine Kowalski

Chief Operations Officer


Christine Kowalski joined Intersect ENT in 2018 with more than thirty years of experience in the medical device industry, including nearly two decades in operations and supply chain executive leadership. Christine has held senior executive leadership roles overseeing operations and supply chains for several medical device companies, including ev3 (acquired by Covidien/Medtronic), American Medical Systems/Endo Healthcare Solutions (acquired by Boston Scientific), RTI Surgical, and Johnson & Johnson, where she served most recently as Vice President of Supply Chain Strategy. During her 18 years at Guidant/Boston Scientific, Christine served as Group Vice President of Operations for Vascular Access, Vice President of Global Operations for Vascular Intervention, General Manager of Guidant Puerto Rico’s manufacturing operation, and Vice President of financial audit and reengineering. She earned a bachelor’s degree from the University of North Dakota and a masters in management from Purdue University’s Krannert School of Management.

James Stambaugh

Senior Vice President, Clinical and Medical Affairs


As our second employee, James has led Intersect ENT’s clinical strategy and programs from inception as well as had far-reaching impact on ensuring patients and physicians have access to our technologies. James has over 20 years’ experience in medical device and pharmaceutical development including regulatory affairs, design and management of human clinical trials, conduct of in-vivo and in-vitro pre-clinical experiments, experience with design controls, design validation, and risk analysis. Prior to joining Intersect ENT, James was Director of Clinical Operations at Guidant’s Vascular Intervention division, responsible for conducting clinical studies for coronary embolic protection, stents, and drug-eluting stents. During his tenure at Guidant, James held various positions within the pre-clinical, clinical and regulatory environment. James started his career as an analytical chemist at an ophthalmic pharmaceutical company, InSite Vision, and later transitioned into clinical research. He holds a B.S. in Chemistry from the University of California at Davis.

Susan Stimson

Chief Strategy Officer


With over 20 years of experience in the healthcare arena, Susan is recognized as a respected leader and expert in the development and commercialization of new medical technologies. Joining Intersect ENT with the founding team in 2007, Susan has played an instrumental role in building the company from R&D stage to a high growth commercial business building the areas of Marketing, Customer Service and International Expansion. She recently led the company’s transition from device to pharmaceutical company as the General Manager for SINUVA and is now heading functions critical to the company’s strategic growth of Market Access, Reimbursement and Business Development.  Susan has impacted top healthcare innovations from the aspects of marketing, sales, R&D, international, clinical research, and manufacturing at both start-up and large companies including many years at Guidant. Ms. Stimson holds a B.S. in Biomedical Engineering from Marquette University.